TrialRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Trial details
- Registry ID
- NCT05733611
- Phase
- Phase 2
Drug research
RP2
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCNCT05733611 | Replimune, Inc. | Phase 2 | Terminated | 2025-08-18Actual |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598 | Replimune, Inc. | Phase 2 | Recruiting | 2027-12-01Estimated |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaNCT06581406 | Replimune, Inc. | Phase 2, Phase 3 | Recruiting | 2030-01Estimated |
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Trial details
- Registry ID
- NCT05733598
- Phase
- Phase 2
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Trial details
- Registry ID
- NCT06581406
- Phase
- Phase 2, Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |